These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15975061)

  • 1. Regression to the mean: implications for clinical trials of psychotropic agents in dementia.
    Cummings JL; Tractenberg RE; Gamst A; Teri L; Masterman D; Thal LJ
    Curr Alzheimer Res; 2004 Nov; 1(4):323-8. PubMed ID: 15975061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients.
    Weiner MF; Tractenberg RE; Sano M; Logsdon R; Teri L; Galasko D; Gamst A; Thomas R; Thal LJ
    J Geriatr Psychiatry Neurol; 2002; 15(2):95-8. PubMed ID: 12083600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.
    Teri L; Logsdon RG; Peskind E; Raskind M; Weiner MF; Tractenberg RE; Foster NL; Schneider LS; Sano M; Whitehouse P; Tariot P; Mellow AM; Auchus AP; Grundman M; Thomas RG; Schafer K; Thal LJ;
    Neurology; 2000 Nov; 55(9):1271-8. PubMed ID: 11087767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.
    Devanand DP; Pelton GH; Cunqueiro K; Sackeim HA; Marder K
    Int J Geriatr Psychiatry; 2011 Sep; 26(9):937-43. PubMed ID: 21845596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease.
    Auchus AP; Bissey-Black C
    J Neuropsychiatry Clin Neurosci; 1997; 9(4):591-3. PubMed ID: 9447502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?
    Sultzer DL; Gray KF; Gunay I; Wheatley MV; Mahler ME
    J Am Geriatr Soc; 2001 Oct; 49(10):1294-300. PubMed ID: 11890487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia.
    Chengappa KN; Goldstein JM; Greenwood M; John V; Levine J
    Clin Ther; 2003 Feb; 25(2):530-41. PubMed ID: 12749512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
    J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haloperidol for agitation in dementia.
    Lonergan E; Luxenberg J; Colford J
    Cochrane Database Syst Rev; 2001; (4):CD002852. PubMed ID: 11687166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
    Tariot PN; Schneider L; Katz IR; Mintzer JE; Street J; Copenhaver M; Williams-Hughes C
    Am J Geriatr Psychiatry; 2006 Sep; 14(9):767-76. PubMed ID: 16905684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.
    Kurlan R; Cummings J; Raman R; Thal L;
    Neurology; 2007 Apr; 68(17):1356-63. PubMed ID: 17452579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial.
    Verhey FR; Verkaaik M; Lousberg R;
    Dement Geriatr Cogn Disord; 2006; 21(1):1-8. PubMed ID: 16244481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.
    Herrmann N; Gauthier S; Boneva N; Lemming OM;
    Int Psychogeriatr; 2013 Jun; 25(6):919-27. PubMed ID: 23472619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia.
    Paunescu H; Dima L; Ghita I; Coman L; Ifteni PI; Fulga I; Coman OA
    Am J Ther; 2020; 27(3):e249-e269. PubMed ID: 32118591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of agitation in dementia.
    Tariot P; Gaile SE; Castelli NA; Porsteinsson AP
    New Dir Ment Health Serv; 1997; (76):109-23. PubMed ID: 9520529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of psychotropic agents to treat agitation and aggression in Brazilian patients with Alzheimer's disease: A naturalistic and multicenter study.
    Oliveira LF; Camargos EF; Martini LLL; Machado FV; Novaes MRCG
    Psychiatry Res; 2021 Jan; 295():113591. PubMed ID: 33271491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer's disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon Patch and combination with mEmantine Comparative Trial study).
    Yoon SJ; Choi SH; Na HR; Park KW; Kim EJ; Han HJ; Lee JH; Shim YS; Na DL
    Geriatr Gerontol Int; 2017 Mar; 17(3):494-499. PubMed ID: 27111084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.